Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 562 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Lupus Erythematosus Clear all
Completed No phase listed Observational Results available

Implementing the Decision-Aid for Lupus (IDEAL Strategy)

NCT03735238
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
SMILE Computerized Decision-Aid
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 15, 2026, 4:47 AM EDT
Withdrawn Phase 2 Interventional

Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE

NCT01702038
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Birmingham, Alabama • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 15, 2026, 4:47 AM EDT
Terminated Phase 2 Interventional Results available

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

NCT05540665
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Daxdilimab, Placebo (Normal Saline)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • San Dimas, California • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 15, 2026, 4:47 AM EDT
Recruiting No phase listed Observational

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

NCT05567198
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus

NCT02319525
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Computerized patient decision-aid, Usual care (lupus pamphlet)
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 15, 2026, 4:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

NCT06839976
View directory record Official record
Conditions
SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19, Cell Therapy, Lupus, Lupus Nephritis (LN)
Interventions
CART19
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 29 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 4:47 AM EDT
Active, not recruiting Phase 4 Interventional

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

NCT06411249
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab (GSK1550188)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
41
States / cities
Anniston, Alabama • Flagstaff, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 15, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prospective Study of Rapamycin for the Treatment of SLE

NCT00779194
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Rapamycin
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 15, 2026, 4:47 AM EDT
Recruiting Not applicable Interventional

Dose Response of Exercise for Arthritis Management

NCT06880653
View directory record Official record
Conditions
Arthritis, Rheumatoid Arthritis (RA), Gout, Fibromyalgia (FM), Osteoarthritis, Lupus Erythematosus, Systemic
Interventions
DREAM Adaptive Intervention
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 15, 2026, 4:47 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

NCT06133972
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Ianalumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
25
States / cities
Anniston, Alabama • Burbank, California • La Palma, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 4:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Belimumab Administered Subcutaneously to Healthy Subjects

NCT01583530
View directory record Official record
Conditions
Healthy
Interventions
Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg, Single Dose Group: Belimumab SC 1 x 200 mg, Multiple Dose Group: Belimumab SC 2 x 120 mg weekly, Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
Biological
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
4
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 15, 2026, 4:47 AM EDT
Withdrawn Phase 2 Interventional

Study of LJP 394 (Abetimus Sodium) in Lupus Patients

NCT00390091
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
abetimus sodium (LJP 394)
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
12 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Los Angeles, California • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 15, 2026, 4:47 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

NCT03843125
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 15, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

NCT02391259
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AMG 557, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 15, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

NCT00979654
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Sifalimumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
24
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 15, 2026, 4:47 AM EDT
Terminated Phase 2 Interventional Results available

Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

NCT05430854
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Daxdilimab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 72 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Upland, California • Clearwater, Florida • Ormond Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 4:47 AM EDT
Recruiting Phase 3 Interventional

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970
View directory record Official record
Conditions
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Interventions
Anifrolumab, Anifrolumab
Combination Product · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 80 Years
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 15, 2026, 4:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional MRI in Lupus Nephritis

NCT01731054
View directory record Official record
Conditions
Healthy, Lupus Nephritis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Los Angelos, California • Torrance, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 15, 2026, 4:47 AM EDT
Withdrawn Phase 4 Interventional

Velcade for Proliferative Lupus Nephritis

NCT01169857
View directory record Official record
Conditions
Lupus Nephritis, Proteinuria, Hematuria
Interventions
Velcade
Drug
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 15, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

NCT06419205
View directory record Official record
Conditions
IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Interventions
ADX-097
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Hollywood, Florida • Lawrenceville, Georgia • Orangeburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 4:47 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

NCT05039840
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
22
States / cities
Vestavia Hills, Alabama • Chandler, Arizona • Mesa, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 4:47 AM EDT
Completed Not applicable Interventional

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

NCT00006133
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older · Female only
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Phase Ib Study of SC Milatuzumab in SLE

NCT01845740
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Lupus Nephritis
Interventions
milatuzumab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 15, 2026, 4:47 AM EDT
Completed Not applicable Interventional

Individual Patient Exposure and Response in Pediatric Lupus

NCT04358302
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Pillsy
Behavioral
Lead sponsor
Duke University
Other
Eligibility
5 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 15, 2026, 4:47 AM EDT